Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria Therapeutics, Inc.

Astria Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutic treatments for rare diseases, while also developing other product candidates for the treatment of serious lipid disorders.

Should you buy, sell, or hold Astria Therapeutics, Inc. (ATXS) ?

Astria Therapeutics, Inc. (ATXS) : Buy or Sell